TY - JOUR
T1 - Conquering homocystinuria with engineered probiotics
AU - Fishbein, Skye R.S.
AU - Evbuomwan, Esse M.
AU - Dantas, Gautam
N1 - Publisher Copyright:
© 2024 Elsevier Inc.
PY - 2024/3/13
Y1 - 2024/3/13
N2 - Pyridoxine-unresponsive homocystinuria has lifelong implications for health. In this issue, Perreault and colleagues present evidence that orally delivered engineered probiotic Escherichia Coli Nissle SYNB1353 is a promising candidate in reducing homocysteine, with successful trials in mice, monkeys, and humans. However, further probiotic optimization and safety assessments are required.
AB - Pyridoxine-unresponsive homocystinuria has lifelong implications for health. In this issue, Perreault and colleagues present evidence that orally delivered engineered probiotic Escherichia Coli Nissle SYNB1353 is a promising candidate in reducing homocysteine, with successful trials in mice, monkeys, and humans. However, further probiotic optimization and safety assessments are required.
UR - http://www.scopus.com/inward/record.url?scp=85187007283&partnerID=8YFLogxK
U2 - 10.1016/j.chom.2024.02.008
DO - 10.1016/j.chom.2024.02.008
M3 - Comment/debate
C2 - 38484708
AN - SCOPUS:85187007283
SN - 1931-3128
VL - 32
SP - 298
EP - 300
JO - Cell Host and Microbe
JF - Cell Host and Microbe
IS - 3
ER -